Global Serum Clot Activator Tubes Market Set to Reach USD 2.5 billion by 2034, Fuelled by Diagnostic Testing Boom
Luton, Bedfordshire, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- The global serum clot activator tubes market is projected to reach a valuation of approximately USD 1.5 billion in 2024. Looking ahead, the market is expected to grow significantly, reaching around USD 2.5 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of approximately 5.2% over the forecast period from 2025 to 2034.
Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/53935/global-serum-clot-activator-tubes-market#request-a-sample
At present, the market is witnessing steady growth, primarily driven by the rising demand for diagnostic testing and continual advancements in laboratory technologies. Key market trends include the increasing adoption of point-of-care testing and a heightened focus on improving the efficiency and accuracy of blood collection procedures.
However, the market faces certain headwinds. Challenges such as stringent regulatory compliance and concerns regarding biohazard waste management could potentially hinder growth.
Despite these constraints, the market presents notable opportunities. Innovations in materials and tube design aimed at enhancing performance, along with the growing shift toward home-based testing solutions, are expected to open new avenues for product development. As the healthcare landscape evolves, these factors will play a pivotal role in shaping the future of the serum clot activator tubes market, fostering an environment ripe for growth and innovation throughout the next decade.
Key Market Drivers:
Diagnostic testing surge: 61% increase in demand for rapid blood analysis
Lab automation adoption: 64% of modern laboratories now use automation-compatible tubes
Preventive healthcare growth: 58% rise in routine screenings driving tube utilization
Chronic disease prevalence: 65% of routine blood tests now require serum separation
Technology and Material Trends:
Plastic dominance: PET tubes now command 69% market share, replacing traditional glass
Enhanced activators: Silica-based formulations improving clotting speed by 42%
Smart integration: 44% of new tubes feature barcode/RFID tracking capabilities
Eco-friendly solutions: 32% of manufacturers now offering sustainable variants
Regional Market Landscape:
North America leads with 34% global share (U.S. accounts for 71% of regional demand)
Europe follows at 28%, driven by stringent quality standards
Asia-Pacific growing fastest (47% demand increase in emerging markets)
Middle East & Africa showing promise with expanding diagnostic infrastructure
Clinical Applications:
Hospitals & clinics: 64% of total usage (78% of labs prefer clot activator tubes)
Chronic disease monitoring: Used in 71% of diabetes/cardiovascular tests
Point-of-care testing: 58% growth in decentralized healthcare settings
Industry Challenges:
Regulatory hurdles: 47% of product launches face approval delays
Cost pressures: 41% of labs report budget constraints
Supply chain disruptions: 33% impact on product availability
Training gaps: 35% of facilities need better staff education
Innovation Spotlight:
BD's 100% recyclable PET tubes reducing lab plastic waste
Greiner Bio-One's micro-sample tubes for paediatric applications
Terumo's 35% production expansion in Southeast Asia
Sarstedt's RFID-enabled tubes enhancing sample traceability
Browse full Report - https://exactitudeconsultancy.com/reports/53935/global-serum-clot-activator-tubes-market
Market Dynamics
One of the primary drivers of the serum clot activator tubes market is the surging demand for diagnostic testing. The growing prevalence of chronic illnesses and the frequent emergence of infectious diseases have underscored the need for widespread and reliable diagnostic procedures. Notably, the COVID-19 pandemic significantly amplified global testing volumes, reinforcing the importance of efficient blood collection systems, including serum clot activator tubes.
Another critical factor fuelling market expansion is the advancement of laboratory technologies. Innovations in blood collection and processing—such as automated collection systems and integrated platforms that streamline sample handling—are improving both the accuracy and speed of diagnostic workflows. These technological upgrades are prompting laboratories to adopt more sophisticated serum tube solutions.
Regulatory developments also shape the market landscape. Stricter compliance standards and heightened focus on patient safety are compelling manufacturers to prioritize product quality and consistency. As a result, there is growing demand for serum clot activator tubes engineered to meet rigorous and evolving regulatory benchmarks.
Lastly, economic trends—particularly increased healthcare spending and infrastructural investments in healthcare systems across various regions—are creating favourable conditions for market growth. With greater budget allocations towards diagnostics and healthcare services, the demand for essential tools like serum clot activator tubes is expected to rise steadily.
Buy Now : https://exactitudeconsultancy.com/purchase/?currency=USD&type=single_user_license&report_id=53935
Future Outlook: The market is poised for continued growth as:
Automation adoption spreads to 63% of global labs
Preventive screening programs expand worldwide
Emerging markets upgrade diagnostic capabilities
Smart technologies (barcoding, RFID) become standard
Sustainable materials gain wider acceptance
Key Players Strategizing for Growth:
BD (Becton, Dickinson and Company)
Terumo Corporation
Greiner Bio-One International GmbH
Sarstedt AG & Co. KG
Roche Diagnostics
Sekisui Medical Co., Ltd.
Qiagen N.V.
Medtronic plc
Hemostatics, Inc.
Cardinal Health
Eurotrol B.V.
Labcorp
Hologic, Inc.
PerkinElmer, Inc.
SUNNY Medical Co., Ltd.
These industry leaders are focusing on:
Automation-compatible designs
Enhanced clotting formulations
Sustainable materials
Emerging market expansion
Smart tracking technologies
Growth Opportunities & Emerging Trends
Opportunities
The serum clot activator tubes market presents numerous growth opportunities fueled by innovation and changing consumer dynamics. One of the key areas of opportunity lies in the development of advanced materials and innovative tube designs. These improvements can enhance clot activation efficiency, optimize sample integrity, and simplify waste disposal—addressing some of the current challenges in clinical workflows.
Another promising avenue is the growing shift toward home-based diagnostic solutions. As consumers increasingly prioritize convenience and accessibility, demand is rising for blood collection devices that are safe and easy to use outside traditional clinical environments. Serum clot activator tubes tailored for home-testing kits offer manufacturers a chance to tap into this expanding segment, easing the burden on healthcare facilities while empowering patients.
Emerging digital health technologies and telemedicine are further transforming the diagnostics landscape. The integration of smart technologies—such as connected blood collection systems and user-friendly digital interfaces—can significantly enhance the patient experience. These innovations not only support remote diagnostics but also align with the broader move toward personalized, patient-centric healthcare.
Additionally, shifts in consumer expectations, including the demand for faster diagnostic results and real-time health monitoring, are reshaping product requirements. The rise of point-of-care testing necessitates the development of specialized serum clot activator tubes that meet the needs of rapid and decentralized testing environments.
Finally, investment in telehealth and remote patient monitoring is creating fertile ground for market expansion. Manufacturers that embrace these trends and align their product strategies with modern healthcare delivery models stand to gain a competitive edge and capture substantial market share in the coming years.
This report is also available in the following languages : Japanese (ロール式昇降装置市場), Korean (롤 리프팅 장비 시장), Chinese (卷筒起重设备市场), French (Marché des équipements de levage de rouleaux), German (Markt für Rollenhebegeräte), and Italian (Mercato delle attrezzature per il sollevamento di rotoli), etc.
Get a Sample PDF Brochure:https://exactitudeconsultancy.com/reports/53935/global-serum-clot-activator-tubes-market#request-a-sample
More Related Reports:
No Additive Collection Tubes Market
The global market for non-additive collection tubes is valued at approximately $2.3 billion in 2024, with projections indicating a compound annual growth rate (CAGR) of 6.5%, pushing the market value to around $4.1 billion by 2034.
https://exactitudeconsultancy.com/reports/53936/global-no-additive-collection-tubes-market
Blood Glucose Collection Tubes Market
The global blood glucose collection tubes market is valued at approximately $1.2 billion. This market is expected to grow significantly, reaching an estimated $2.5 billion by 2034, driven by the increasing prevalence of diabetes and the demand for reliable and efficient blood sampling solutions. The forecasted Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is projected at 7.5%, reflecting a robust growth trajectory propelled by advancements in healthcare technology and continuous innovations in product designs.
https://exactitudeconsultancy.com/reports/53937/global-blood-glucose-collection-tubes-market
Wearable Smart Patch Market
The global wearable smart patch market is valued at approximately $3 billion, with an anticipated growth trajectory fueled by advancements in healthcare technology and increasing consumer demand for remote monitoring solutions. The projected market value is expected to reach around $10 billion by 2034, indicating significant expansion over the next decade.
https://exactitudeconsultancy.com/reports/53938/global-wearable-smart-patch-market
Patch Thermometer Market
The global patch thermometer market is valued at approximately $320 million in 2024 and is projected to reach around $520 million by 2034. This reflects a robust Compound Annual Growth Rate (CAGR) of 5.1% over the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53939/global-patch-thermometer-market
Fully Automated Clinical Chemistry Analyzer Market
The global market for fully automated clinical chemistry analyzers was valued at approximately $9.3 billion in 2024. Projections indicate substantial growth, with a forecasted market value of around $14.2 billion by 2034, reflecting increasing integration of automation in laboratory settings. The projected compound annual growth rate (CAGR) for the period from 2025 to 2034 is estimated at 5.6%.
https://exactitudeconsultancy.com/reports/53943/global-fully-automated-clinical-chemistry-analyzer-market
Mobile MRI Scanner Market
The global mobile MRI scanner market is projected to reach a valuation of approximately $2.5 billion in 2024, with a robust forecast to grow to around $4.5 billion by 2034. This represents a compound annual growth rate (CAGR) of about 6.3% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53944/global-mobile-mri-scanner-market
Medical Gas Monitoring System Market
The global medical gas monitoring system market is valued at approximately $550 million in 2024. This market is projected to reach around $1.2 billion by 2034, driven by an increasing emphasis on patient safety and regulatory compliance in healthcare settings. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is expected to be approximately 8.5%.
https://exactitudeconsultancy.com/reports/53951/global-medical-gas-monitoring-system-market
Portable ATP Hygiene Monitoring System Market
The global market for portable ATP hygiene monitoring systems is valued at approximately $250 million. The market is expected to grow significantly over the forecast period, with a projected value of about $500 million by 2034. This growth trajectory reflects a Compound Annual Growth Rate (CAGR) of approximately 7.4%, driven by increasing awareness of hygiene standards in various sectors, including food and beverage, pharmaceuticals, and healthcare.
https://exactitudeconsultancy.com/reports/53955/global-portable-atp-hygiene-monitoring-system-market
Medical Ceiling Supply Unit Market
The global medical ceiling supply unit market is valued at approximately $6.5 billion, reflecting an increasing demand driven by advancements in healthcare infrastructure and the rising emphasis on infection control in medical facilities. The market is anticipated to grow significantly over the forecast period from 2025 to 2034, with a projected market value reaching approximately $10.2 billion by 2034. This translates to a Compound Annual Growth Rate (CAGR) of around 5.1%.
https://exactitudeconsultancy.com/reports/53956/global-medical-ceiling-supply-unit-market
Medical Supply Pendants Market
The global medical supply pendants market is valued at approximately $580 million in 2024, with expectations to reach around $970 million by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of approximately 5.2% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53958/global-medical-supply-pendants-market
Automatic Visual Vial Inspection Machine Market
The global market for Automatic Visual Vial Inspection Machines was valued at approximately $580 million in 2024 and is projected to reach around $1.1 billion by 2034. This indicates a remarkable growth trajectory, with a Compound Annual Growth Rate (CAGR) of approximately 6.7% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53978/global-automatic-visual-vial-inspection-machine-market
Patient Isolation Room Market
The global patient isolation room market is valued at approximately $2.5 billion in 2024, with projections estimating it will reach around $5 billion by 2034. This growth represents a compound annual growth rate (CAGR) of approximately 7.4% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53987/global-patient-isolation-room-market
Portable Negative Air Machine Market
The global portable negative air machine market is valued at approximately $450 million in 2024 and is projected to reach around $750 million by 2034, reflecting increasing awareness of indoor air quality and air purification technologies. The market is expected to experience a Compound Annual Growth Rate (CAGR) of about 5.2% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53990/global-portable-negative-air-machine-market
Medical Tent Market
The global medical tent market is valued at approximately $1.5 billion in 2024, with projections indicating a market value of around $2.8 billion by 2034. This growth trajectory reflects a compound annual growth rate (CAGR) of approximately 6.8% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53991/global-medical-tent-market
Dental Examination Gloves Market
The global dental examination gloves market is valued at approximately $1.1 billion in 2024, driven by a rising demand for infection control and enhanced patient safety protocols. The market is projected to reach about $1.7 billion by 2034, reflecting increasing awareness among dental professionals regarding hygiene standards and the use of advanced materials for glove manufacturing.
https://exactitudeconsultancy.com/reports/53993/global-dental-examination-gloves-market
Modular Isolation Room Market
The global modular isolation room market is projected to reach a value of approximately $4.5 billion in 2024, driven by an increasing demand for efficient healthcare solutions amidst rising infection control challenges. The market is expected to experience significant growth, with a projected value of around $9.7 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 8.3% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/53997/global-modular-isolation-room-market
Negative Pressure Isolation Room Market
The global market for Negative Pressure Isolation Rooms (NPIRs) is valued at approximately $1.2 billion in 2024, with projections estimating a growth to around $2.1 billion by 2034. This trajectory reflects a robust Compound Annual Growth Rate (CAGR) of approximately 6.0% between 2025 and 2034.
https://exactitudeconsultancy.com/reports/53998/global-negative-pressure-isolation-room-market
Pharmaceutical Cleanroom Air Shower Market
The global pharmaceutical cleanroom air shower market is valued at approximately $250 million in 2024 and is expected to reach around $400 million by 2034, indicating a robust growth trajectory. This growth corresponds to a Compound Annual Growth Rate (CAGR) of approximately 5.0% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/54009/global-pharmaceutical-cleanroom-air-shower-market
In-ear Hearing Aids Market
The global in-ear hearing aids market is valued at approximately $6.5 billion in 2024, driven by an increasing prevalence of hearing loss and an aging population. As healthcare systems enhance accessibility and awareness of auditory technologies, the market is poised for significant growth. Between 2025 and 2034, the market is projected to reach around $10 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of 5.4%.
https://exactitudeconsultancy.com/reports/54013/global-in-ear-hearing-aids-market
Automatic Tablet Hardness Tester Market
The global market for automatic tablet hardness testers is valued at approximately $180 million in 2024, with a projected growth to around $290 million by 2034. This anticipated increase reflects a significant Compound Annual Growth Rate (CAGR) of about 4.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/54015/global-automatic-tablet-hardness-tester-market
CONTACT: Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@exactitudeconsultancy.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
LGMS Berhad's (KLSE:LGMS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
LGMS Berhad (KLSE:LGMS) has had a rough week with its share price down 3.2%. However, stock prices are usually driven by a company's financials over the long term, which in this case look pretty respectable. Specifically, we decided to study LGMS Berhad's ROE in this article. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Simply put, it is used to assess the profitability of a company in relation to its equity capital. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for LGMS Berhad is: 12% = RM12m ÷ RM96m (Based on the trailing twelve months to March 2025). The 'return' is the profit over the last twelve months. Another way to think of that is that for every MYR1 worth of equity, the company was able to earn MYR0.12 in profit. View our latest analysis for LGMS Berhad We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes. At first glance, LGMS Berhad seems to have a decent ROE. And on comparing with the industry, we found that the the average industry ROE is similar at 12%. Consequently, this likely laid the ground for the decent growth of 7.7% seen over the past five years by LGMS Berhad. As a next step, we compared LGMS Berhad's net income growth with the industry and were disappointed to see that the company's growth is lower than the industry average growth of 30% in the same period. The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. If you're wondering about LGMS Berhad's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry. While LGMS Berhad has a three-year median payout ratio of 51% (which means it retains 49% of profits), the company has still seen a fair bit of earnings growth in the past, meaning that its high payout ratio hasn't hampered its ability to grow. Along with seeing a growth in earnings, LGMS Berhad only recently started paying dividends. Its quite possible that the company was looking to impress its shareholders. Existing analyst estimates suggest that the company's future payout ratio is expected to drop to 30% over the next three years. Regardless, the ROE is not expected to change much for the company despite the lower expected payout ratio. Overall, we feel that LGMS Berhad certainly does have some positive factors to consider. Its earnings growth is decent, and the high ROE does contribute to that growth. However, investors could have benefitted even more from the high ROE, had the company been reinvesting more of its earnings. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
4 hours ago
- Yahoo
Returns Are Gaining Momentum At Abundance International (Catalist:541)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. So when we looked at Abundance International (Catalist:541) and its trend of ROCE, we really liked what we saw. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. Analysts use this formula to calculate it for Abundance International: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.028 = US$1.2m ÷ (US$75m - US$34m) (Based on the trailing twelve months to December 2024). So, Abundance International has an ROCE of 2.8%. Ultimately, that's a low return and it under-performs the Trade Distributors industry average of 4.2%. See our latest analysis for Abundance International Historical performance is a great place to start when researching a stock so above you can see the gauge for Abundance International's ROCE against it's prior returns. If you're interested in investigating Abundance International's past further, check out this free graph covering Abundance International's past earnings, revenue and cash flow. We're delighted to see that Abundance International is reaping rewards from its investments and is now generating some pre-tax profits. About five years ago the company was generating losses but things have turned around because it's now earning 2.8% on its capital. Not only that, but the company is utilizing 31% more capital than before, but that's to be expected from a company trying to break into profitability. This can tell us that the company has plenty of reinvestment opportunities that are able to generate higher returns. On a side note, Abundance International's current liabilities are still rather high at 45% of total assets. This can bring about some risks because the company is basically operating with a rather large reliance on its suppliers or other sorts of short-term creditors. While it's not necessarily a bad thing, it can be beneficial if this ratio is lower. Long story short, we're delighted to see that Abundance International's reinvestment activities have paid off and the company is now profitable. And since the stock has fallen 44% over the last five years, there might be an opportunity here. With that in mind, we believe the promising trends warrant this stock for further investigation. On a final note, we've found 2 warning signs for Abundance International that we think you should be aware of. While Abundance International may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Returns Are Gaining Momentum At Abundance International (Catalist:541)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. So when we looked at Abundance International (Catalist:541) and its trend of ROCE, we really liked what we saw. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. Analysts use this formula to calculate it for Abundance International: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.028 = US$1.2m ÷ (US$75m - US$34m) (Based on the trailing twelve months to December 2024). So, Abundance International has an ROCE of 2.8%. Ultimately, that's a low return and it under-performs the Trade Distributors industry average of 4.2%. See our latest analysis for Abundance International Historical performance is a great place to start when researching a stock so above you can see the gauge for Abundance International's ROCE against it's prior returns. If you're interested in investigating Abundance International's past further, check out this free graph covering Abundance International's past earnings, revenue and cash flow. We're delighted to see that Abundance International is reaping rewards from its investments and is now generating some pre-tax profits. About five years ago the company was generating losses but things have turned around because it's now earning 2.8% on its capital. Not only that, but the company is utilizing 31% more capital than before, but that's to be expected from a company trying to break into profitability. This can tell us that the company has plenty of reinvestment opportunities that are able to generate higher returns. On a side note, Abundance International's current liabilities are still rather high at 45% of total assets. This can bring about some risks because the company is basically operating with a rather large reliance on its suppliers or other sorts of short-term creditors. While it's not necessarily a bad thing, it can be beneficial if this ratio is lower. Long story short, we're delighted to see that Abundance International's reinvestment activities have paid off and the company is now profitable. And since the stock has fallen 44% over the last five years, there might be an opportunity here. With that in mind, we believe the promising trends warrant this stock for further investigation. On a final note, we've found 2 warning signs for Abundance International that we think you should be aware of. While Abundance International may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
